搜索
Alterity Therapeutics Ltd
ATHE添加自选
4.415USD
-0.070-1.56%
收盘 07-31 16:00（美东）报价延迟15分钟
67.16M总市值
亏损市盈率 TTM
关于 Alterity Therapeutics Ltd 公司
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd简介
公司代码ATHE
公司名称Alterity Therapeutics Ltd
上市日期Mar 28, 2000
CEOStamler (David A)
员工数量9
证券类型Depository Receipt
年结日Mar 28
公司地址Level 14, 350 Collins Street
城市MELBOURNE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Australia
邮编3000
电话61393494906
网址https://alteritytherapeutics.com/
公司代码ATHE
上市日期Mar 28, 2000
CEOStamler (David A)
Alterity Therapeutics Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
常见问题
Alterity Therapeutics Ltd的前五大股东是谁？
Alterity Therapeutics Ltd 的前五大股东如下：Mr. Peter Ashley Marks
有多少机构持有Alterity Therapeutics Ltd(ATHE)的股份？
截至2026Q1，共有32家机构持有Alterity Therapeutics Ltd的股份，合计持有的股份价值约为327.31K，占公司总股份的1.81%。与2025Q4相比，机构持股有所增加，增幅为-185355.00。